Americans are split on using weight loss drugs such as Ozempic and Wegovy to treat obesity or weight-related conditions, according to a new survey that was published on Friday. The new ...

The FDA has approved a new type of painkiller that doesn't come with the risks of addiction and overdose associated with opioids.

The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...

The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.

The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or ...

The medication offers relatively modest pain relief, underscoring the challenges of finding new ways to manage pain.

The AP-NORC poll shows about half of Americans “strongly” or “somewhat” favor having the federal programs Medicare and Medicaid cover weight-loss drugs for people who have obesity, while about 2 in 10 ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, will host a virtual investor event and conference ...

Additionally, rising uncertainty over potential economic policies from the new U.S. administration has impacted overall sentiment,” said Vinod Nair, head of research, Geojit Financial Services.

The Biden administration moved Friday to negotiate the prices Medicare pays for the blockbuster weight-loss drugs Ozempic and ...

Diabetes and weight loss drugs Ozempic and Wegovy have been ... “In 2026, people with Medicare prescription drug coverage are expected to see aggregated estimated savings of $1.5 billion in ...

Mifepristone, usually combined with a second drug, accounts for over three-fifths of all abortions in the U.S. Some states are seeking to limit its availability through new legislation ...